AbbVie Dirección

Dirección controles de criterios 2/4

El CEO de AbbVie's es Rick Gonzalez , nombrado en Jan 2013, tiene una permanencia de 11.25 años. compensación anual total es $25.66M, compuesta por 6.6% salario y 93.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de MX$1.59B. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 11.3 años, respectivamente.

Información clave

Rick Gonzalez

Chief Executive Officer (CEO)

US$25.7m

Compensación total

Porcentaje del salario del CEO	6.6%
Permanencia del CEO	11.3yrs
Participación del CEO	0.03%
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	11.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rick Gonzalez en comparación con los beneficios de AbbVie?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$26m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$9b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$26m	US$2m	US$12b
Sep 30 2022	n/a	n/a	US$13b
Jun 30 2022	n/a	n/a	US$13b
Mar 31 2022	n/a	n/a	US$12b
Dec 31 2021	US$24m	US$2m	US$11b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$24m	US$2m	US$5b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$22m	US$2m	US$8b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$5b
Dec 31 2018	US$21m	US$2m	US$6b
Sep 30 2018	n/a	n/a	US$8b
Jun 30 2018	n/a	n/a	US$6b
Mar 31 2018	n/a	n/a	US$6b
Dec 31 2017	US$23m	US$2m	US$5b

Compensación vs. Mercado: La compensación total de Rick($USD25.66M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD6.04M).

Compensación vs. Ingresos: La compensación de Rick ha sido consistente con los resultados de la empresa en el último año.

CEO

Rick Gonzalez (69 yo)

11.3yrs

Permanencia

US$25,661,972

Compensación

Mr. Richard A. Gonzalez, also known as Rick, serves as Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of Phar...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Richard Gonzalez	Chairman & CEO	11.3yrs	US$25.66m	0.031% $ 1.5b
Robert Michael	President & COO	1.9yrs	US$14.44m	0.0056% $ 273.4m
Scott Reents	Executive VP & CFO	1.9yrs	US$10.19m	0.00087% $ 42.7m
Azita Saleki-Gerhardt	Executive VP & COO	less than a year	US$9.30m	0.013% $ 626.8m
Jeffrey Stewart	Executive VP & Chief Commercial Officer	no data	US$15.35m	0.0035% $ 172.8m
Thomas Hudson	Senior VP & Chief Scientific Officer of Global Research	no data	sin datos	0.0061% $ 297.4m
Elizabeth Shea	Senior Vice President of Investor Relations	no data	sin datos	sin datos
Perry Siatis	Executive VP	1.6yrs	sin datos	0% $ 0
Sanjay Narayan	Senior VP	less than a year	sin datos	sin datos
Timothy Richmond	Executive VP & Chief Human Resources Officer	no data	US$3.30m	0.00078% $ 38.3m
Wulff-Erik von Borcke	Senior VP of AbbVie & President of Oncology	less than a year	sin datos	sin datos
Nicholas Donoghoe	Executive VP and Chief Business & Strategy Officer	1.3yrs	sin datos	0.0032% $ 155.1m

1.5yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ABBV * no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Richard Gonzalez	Chairman & CEO	11.3yrs	US$25.66m	0.031% $ 1.5b
Roxanne Austin	Independent Director	11.3yrs	US$385.59k	0.00065% $ 31.9m
Thomas Freyman	Independent Director	4yrs	US$380.78k	0.0071% $ 347.0m
Glenn Tilton	Lead Independent Director	11.3yrs	US$418.94k	0.0014% $ 69.2m
Edward Rapp	Independent Director	11.3yrs	US$394.98k	0.00090% $ 44.2m
William H. Burnside	Independent Director	11.3yrs	US$377.48k	0% $ 0
Frederick Waddell	Independent Director	11.3yrs	US$369.98k	0.00011% $ 5.4m
Melody Meyer	Independent Director	7yrs	US$369.98k	0% $ 0
Brett Hart	Independent Director	8.3yrs	US$380.78k	0% $ 0
Rebecca Roberts	Independent Director	6yrs	US$359.98k	sin datos
Robert Alpern	Independent Director	11.3yrs	US$461.18k	0.000010% $ 490.8k
Jennifer Davis	Independnet Director	less than a year	sin datos	sin datos

11.3yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de ABBV * son experimentados ( 11.3 años antigüedad media).

AbbVie Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

Executive VP & Chief Commercial Officer recently sold Mex$99m worth of stock

AbbVie Inc., Annual General Meeting, May 03, 2024

Chairman & CEO recently sold Mex$420m worth of stock

AbbVie Inc. Announces Chief Executive Officer Changes

Abbvie, Inc. Appoints Robert A. Michael as Member of the Board of Directors and Richard A. Gonzalez as Executive Chairman of the Board of Directors

Recent updates

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings released: EPS: US$0.77 (vs US$0.13 in 1Q 2023)

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Executive VP & Chief Commercial Officer recently sold Mex$99m worth of stock

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Chairman & CEO recently sold Mex$420m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

AbbVie Inc. Announces Chief Executive Officer Changes

Abbvie, Inc. Appoints Robert A. Michael as Member of the Board of Directors and Richard A. Gonzalez as Executive Chairman of the Board of Directors

Fourth quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2024

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie's VYALEV™? (foslevodopa/Foscarbidopa Solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

AbbVie Inc. Reports Unaudited Intangible Asset Impairment for the Quarter Ended December 31, 2023

AbbVie Inc. Launches Produodopa (Foslevodopa/Foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Abbvie Inc. Announces Phase 2 Results Showing Adults with Moderate to Severe Hidradenitis Suppurativa

AbbVie Inc. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of US$1.55 per share at 3.8% yield

Insider recently sold Mex$7.6m worth of stock

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

AbbVie Inc. Announces Positive Topline Results from Phase 2 Luminosity Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer

AbbVie Announces U.S. Food and Drug Administration and European Medicines Agency Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

AbbVie Announces Results Evaluating the Efficacy, Safety, and Tolerability of UBRELVY

Abbvie Inc. Declares Quarterly Dividend, Payable on February 15, 2024

Third quarter 2023 earnings released: EPS: US$1.00 (vs US$2.22 in 3Q 2022)

New minor risk - Profit margin trend

Lupus Therapeutics Partners with AbbVie Inc. on Clinical Trial Recruitment Efforts in SLE Through Lucin Lupus Clinical Trial Network

Abbvie Inc. Epkinly™ (Epcoritamab Injection/Epcoritamab for Injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)

AbbVie Presents Positive Results from Head-to-Head Phase 3 Sequence Study in Crohn's Disease Meets All Primary and Secondary Endpoints

AbbVie Inc. Announces Director Appointments

AbbVie Inc. Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (Upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

AbbVie Inc. (NYSE:ABBV) acquired Mitokinin, Inc. for $655 million.

AbbVie Inc. to Report Q3, 2023 Results on Oct 27, 2023

Upcoming dividend of US$1.48 per share at 4.0% yield

Abbvie Presents Results from Phase 3 Canova Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

AbbVie Announces European Commission Approval of TEPKINLY (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Abbvie Inc. Announces Top-Line Results from the Phase 3 Sequence Clinical Trial Evaluating Risankizumab

AbbVie Inc. Declares Quarterly Dividend, Payable on November 15, 2023

AbbVie Inc. Submits Regulatory Applications to FDA and Ema for Risankizumab (Skyrizi®) in Ulcerative Colitis

Abbvie Inc. Announces European Commission Approves AQUIPTA for the Prophylaxis of Migraine in Adults

Chairman & CEO recently sold Mex$197m worth of stock

Second quarter 2023 earnings released: EPS: US$1.14 (vs US$0.52 in 2Q 2022)

AbbVie Announces the British Journal of Dermatology Publishes Results from the Head-To-Head Phase 4 IMMpulse Study

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad